Skip to main content
OpenTrials
Completed

NCT Number: NCT03713242

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild, moderate, and severe hepatic impairment due to liver cirrhosis on the pharmacokinetics of ACT-541468.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University Hospital Basel

Basel, 4031, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent prior to any study-mandated procedure.
  • Male and female subjects aged between 18 and 75 years (inclusive) at screening.
  • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (from screening, during the entire study, and for at least one month after last study treatment intake) a highly effective method of contraception, be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential.
  • Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening.
  • For healthy subjects: Normal renal function confirmed by a creatinine clearance at screening according to Cockroft and Gault adjusted to age of:
  • ≥ 80 mL/min/1.73 m2 for subjects ≤ 50 years of age.
  • ≥ 70 mL/min/1.73 m2 for subjects 51-60 years of age.
  • ≥ 60 mL/min/1.73 m2 for subjects 61-75 years of age.
  • For subjects with hepatic impairment: Degree of liver function impairment due to liver cirrhosis according to the Child-Pugh classification:
  • Group A: Mild hepatic impairment, Child-Pugh score 5-6.
  • Group B: Moderate hepatic impairment, Child-Pugh score 7-9.
  • Group C: Severe hepatic impairment, Child-Pugh score 10-15.

Exclusion criteria

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • For subjects with hepatic impairment: History of major medical or surgical disorders, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment except for those related to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • For healthy subjects:
  • History of alcoholism or drug abuse within the 3-year period prior to screening.
  • Relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.

Treatment and study plan

ACT-541468 25 mg

Drug

Administered as a tablet.

ACT-541468 25 mg (or 10 mg depending on interim results)

Drug

Administered as a tablet.

Primary outcomes

  1. Treatment-emergent adverse events (AEs)

    Time frame: From study treatment administration up to EOS (duration: up to 4 days)

  2. Treatment-emergent serious adverse events (SAEs)

    Time frame: From study treatment administration up to EOS (duration: up to 4 days)

Other outcomes

  1. Plasma pharmacokinetics: AUC(0-t)

    Time frame: At various timepoints (duration: up to 4 days)

  2. Plasma pharmacokinetics: AUC(0-inf)

    Time frame: At various timepoints (duration: up to 4 days)

  3. Plasma pharmacokinetics: AUC(0-24)

    Time frame: At various timepoints (duration: up to 4 days)

  4. Plasma pharmacokinetics: Cmax

    Time frame: At various timepoints (duration: up to 4 days)

  5. Plasma pharmacokinetics: Tmax

    Time frame: At various timepoints (duration: up to 4 days)

  6. Plasma pharmacokinetics: T1/2

    Time frame: At various timepoints (duration: up to 4 days)

  7. Plasma pharmacokinetics: Cu/C (extent of plasma protein binding)

    Time frame: At various timepoints (duration: up to 4 days)

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

A Single-center, Open-label, Single-dose, Phase 1 Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Oct 19, 2018
Registry last updated
Jul 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.